Brief: Betterlife Pharma Initiates Preclinical Study Of AP-003 (Rhifna2b) Against Delta Variant Of Sars-Cov-2
25/08/2021 13:44
Aug 25 (Reuters) - BetterLife Pharma Inc BETR.CD :
* BETTERLIFE INITIATES PRECLINICAL STUDY OF AP-003
(RHIFNA2B)
AGAINST DELTA VARIANT OF SARS-COV-2
Source text for Eikon: ID:nGNX7W983m
Further company coverage: BETR.CD
((reuters.briefs@thomsonreuters.com;))
Recent news on BetterLife Pharma
See all newsBrief: Betterlife Pharma Provides Scientific Update On Neuroplastogenic Activity Of BETR-001
Brief: Betterlife Pharma Advanced In IND-enabling Studies For BETR-001
Brief: BetterLife Announces Closing Of $1.168 Million Convertible Debentures To Further Advance IND-Enabling Studies Of Its Non-Hallucinogenic LSD-Based Drug Candidate BETR-001
Brief: Omineca Announces $2 Mln Brokered Financing Of Flow-Through Units
Brief: Betterlife Announces Pricing Of Proposed Offering Of Units